SEA Hero image
SEA Hero image


Backed by real-world, long-term,
and clinical trial evidence—
NUCALA protects your SEA
patients from exacerbations

Backed by real-world, long-term, and clinical trial evidence—NUCALA protects your SEA patients from exacerbations

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Choose NUCALA for SEA

Choose NUCALA for SEA

Red lung icon

Exacerbation reduction

Trial 2: 53% reduction in exacerbations vs placebo

(P<0.001; Primary Endpoint)1*

Real-world study2

Down Arrow



in exacerbations

at 2 years vs baseline

Secondary objective.

Results are descriptive.

See study limitations and primary objective

Two pills icon

OCS reduction

Trial 3: Greater reduction in daily OCS dose while maintaining asthma control vs placebo (P=0.008; Primary Endpoint; Weeks 20-24)3

Real-world study2

Down Arrow



in daily maintenance
OCS dose at 2 years vs baseline§

Secondary objective.

Results are descriptive.

See study limitations and primary objective

Red calendar icon

Long-term data

4.5-year open-label study:
Exacerbation rate 0.68/year (Secondary Endpoint)4II

Associated with

Down Arrow



in annual exacerbation

rate vs baseline4II

Results are descriptive.

Median duration 3.8 years.2

Real-world study:  2-year, prospective, observational, cohort study (N=822). Primary objective: Post-exposure NUCALA 1.24 vs baseline 4.29 (71% reduction; rate ratio 0.29; 95% CI: 0.26, 0.32). Secondary objectives shown above: Exacerbation rate at 2 years post-exposure: NUCALA 1.11 vs baseline 4.29 (74% reduction; rate ratio 0.26; 95% CI: 0.24, 0.29); daily median maintenance OCS use among users at baseline: 0.0 mg/day at Weeks 101-104 (n=168) vs baseline 10 mg/day (n=297). Results are descriptive. Study limitations: Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2

§Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.2


II4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Select secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.2,4 Results are descriptive.

*Trial 2: 32-week placebo-controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA + SOC 0.83/year, placebo + SOC 1.74/year, P<0.001.1

Trial 3: 24-week placebo-controlled study (N=135).3

1-year pre-exposure (baseline) rate based on 1-year analysis model.2


The targeted therapy for 4 eosinophil-driven diseases

NUCALA is for the:

See Important Safety Info

Red checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your SEA patients and practice

See patient access & support

NUCALA Red Autoinjector icon

Administering NUCALA 

NUCALA gives appropriate patients the option to self-administer at home.

See SEA dosing & administration

CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.